Meeting
2022 ASCO Annual Meeting
Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non–small cell lung cancer.
Authors
Changhee Park
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Changhee Park , Dong Young Jeong , Yeonu Choi , You Jin Oh , Jonghoon Kim , Sergio Pereira , Kyunghyun Paeng , Chan-Young Ock , Se-Hoon Lee , Ho Yun Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2663)
DOI
10.1200/JCO.2022.40.16_suppl.2663
Abstract #
2663
Poster Bd #
317
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.
First Author: Amogh Hiremath
Poster
2022 ASCO Annual Meeting
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
First Author: Elio Adib
Poster
2021 ASCO Annual Meeting
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
First Author: Jeanne Shen
Poster
2020 ASCO Virtual Scientific Program
Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.
First Author: Yuki Miyai